$HMELF
Hold Me Ltd

2023 Q4 Form 20-F Financial Statement

#000182912624003405 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022 Q4
Revenue $927.0K
YoY Change 753.03%
Cost Of Revenue $213.3K
YoY Change 34.27%
Gross Profit $713.7K
YoY Change -1520.95%
Gross Profit Margin 76.99%
Selling, General & Admin $432.1K
YoY Change -28.45%
% of Gross Profit 60.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $432.1K
YoY Change -28.45%
Operating Profit $281.6K
YoY Change -143.05%
Interest Expense $74.13K
YoY Change 52.77%
% of Operating Profit 26.33%
Other Income/Expense, Net -$84.34K
YoY Change 33.0%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings $197.2K
YoY Change -127.71%
Net Earnings / Revenue 21.28%
Basic Earnings Per Share $0.02
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 2.282M shares 2.282M shares 2.282M shares
Diluted Shares Outstanding 1.002B shares

Balance Sheet

Concept 2023 Q4 2023 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $135.8K $451.8K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $0.00
Receivables
Other Receivables $2.676K
Total Short-Term Assets $734.8K $702.7K
YoY Change 4.57% -15.86%
LONG-TERM ASSETS
Property, Plant & Equipment $1.419K $3.395K
YoY Change -58.2% -98.31%
Goodwill
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $254.2K $3.395K
YoY Change 7386.63% -98.31%
TOTAL ASSETS
Total Short-Term Assets $734.8K $702.7K
Total Long-Term Assets $254.2K $3.395K
Total Assets $989.0K $706.1K
YoY Change 40.06% -31.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $13.89K $37.58K
YoY Change -63.03% 2.82%
Total Short-Term Liabilities $2.851M $2.749M
YoY Change 3.71% 18.0%
LONG-TERM LIABILITIES
Long-Term Debt $16.22K
YoY Change -69.68%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $16.22K
YoY Change -100.0% -69.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.851M $2.749M
Total Long-Term Liabilities $0.00 $16.22K
Total Liabilities $2.851M $2.765M
YoY Change 3.1% 16.04%
SHAREHOLDERS EQUITY
Retained Earnings -$3.034M -$3.231M
YoY Change -6.1% 28.25%
Common Stock $22.82K $22.82K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.862M -$2.059M
YoY Change
Total Liabilities & Shareholders Equity $989.0K $706.1K
YoY Change 40.06% -31.84%

Cashflow Statement

Concept 2023 Q4 2023 2022 Q4
OPERATING ACTIVITIES
Net Income $197.2K
YoY Change -127.71%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $886.9K
YoY Change -352.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$800.0K
YoY Change -1798.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -393.3K
YoY Change 1346.09%
NET CHANGE
Cash From Operating Activities 886.9K
Cash From Investing Activities -800.0K
Cash From Financing Activities -393.3K
Net Change In Cash -316.0K
YoY Change -4.72%
FREE CASH FLOW
Cash From Operating Activities $886.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001853630
CY2022Q4 cik0001853630 Loans Granted
LoansGranted
CY2022Q4 cik0001853630 Investment And Advances In Account Of Investment
InvestmentAndAdvancesInAccountOfInvestment
CY2022Q4 cik0001853630 Long Term Loans Granted
LongTermLoansGranted
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
CY2023 us-gaap Other Income
OtherIncome
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
CY2022 us-gaap Financing Interest Expense
FinancingInterestExpense
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2022 cik0001853630 Repaymentsof Investment And Advances In Account Of Investment
RepaymentsofInvestmentAndAdvancesInAccountOfInvestment
CY2022 cik0001853630 Increase Decrease In Loans Granted
IncreaseDecreaseInLoansGranted
CY2022 cik0001853630 Short Term Loan From Related Parties And Shareholders Loan
ShortTermLoanFromRelatedPartiesAndShareholdersLoan
CY2023 cik0001853630 Short Term Credit From Banking Institutions
ShortTermCreditFromBankingInstitutions
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2023Q4 cik0001853630 Prepaid Revenue
PrepaidRevenue
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
CY2023 us-gaap Communication
Communication
CY2023 cik0001853630 Maintenance And Electricity
MaintenanceAndElectricity
CY2022 cik0001853630 Office Expenses
OfficeExpenses
CY2022 us-gaap Other Expenses
OtherExpenses
CY2023 us-gaap Taxes Excluding Income And Excise Taxes
TaxesExcludingIncomeAndExciseTaxes
CY2023 cik0001853630 Travel And Parking
TravelAndParking
CY2022 cik0001853630 Interest Income From Loans Granted
InterestIncomeFromLoansGranted
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2023 dei Document Type
DocumentType
20-F
CY2023 dei Document Registration Statement
DocumentRegistrationStatement
false
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Document Shell Company Report
DocumentShellCompanyReport
false
CY2023 dei Entity File Number
EntityFileNumber
333-255462
CY2023 dei Entity Registrant Name
EntityRegistrantName
Hold Me Ltd.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L3
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
30 Golomb Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ness Ziyona
CY2023 dei Entity Address Country
EntityAddressCountry
IL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7401337
CY2023 dei Security12b Title
Security12bTitle
Ordinary Shares, par value NIS 0.01 per share.
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2282124 shares
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Document Accounting Standard
DocumentAccountingStandard
U.S. GAAP
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023 dei Auditor Firm
AuditorFirmId
2015
CY2023 dei Auditor Name
AuditorName
BARZILY AND CO
CY2023 dei Auditor Location
AuditorLocation
Jerusalem, Israel
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135832
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
451784
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
3030
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
3030
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
44460
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
247867
CY2023Q4 cik0001853630 Loans Granted
LoansGranted
551463
CY2023Q4 us-gaap Assets Current
AssetsCurrent
734785
CY2022Q4 us-gaap Assets Current
AssetsCurrent
702681
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1419
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3395
CY2023Q4 cik0001853630 Investment And Advances In Account Of Investment
InvestmentAndAdvancesInAccountOfInvestment
205000
CY2023Q4 cik0001853630 Long Term Loans Granted
LongTermLoansGranted
47752
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
254171
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3395
CY2023Q4 us-gaap Assets
Assets
988956
CY2022Q4 us-gaap Assets
Assets
706076
CY2023Q4 cik0001853630 Short Term Loans From Banking Institutions
ShortTermLoansFromBankingInstitutions
16622
CY2022Q4 cik0001853630 Short Term Loans From Banking Institutions
ShortTermLoansFromBankingInstitutions
46618
CY2023Q4 cik0001853630 Trade Payables
TradePayables
14505
CY2022Q4 cik0001853630 Trade Payables
TradePayables
2604
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
2819547
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
2699585
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2850674
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2748807
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16218
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
100000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
100000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
990000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
990000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2282124 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2282124 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2282124 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2282124 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22821
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22821
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1049703
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1049703
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3034242
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3231473
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1861718
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2058949
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
988956
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
706076
CY2023 us-gaap Revenues
Revenues
927000
CY2022 us-gaap Revenues
Revenues
108671
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
213344
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
158895
CY2023 us-gaap Gross Profit
GrossProfit
713656
CY2022 us-gaap Gross Profit
GrossProfit
-50224
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
432088
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
603867
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
281568
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-654091
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-84337
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63412
CY2023 us-gaap Profit Loss
ProfitLoss
197231
CY2022 us-gaap Profit Loss
ProfitLoss
-717503
CY2022 us-gaap Other Income
OtherIncome
5613
CY2023 us-gaap Net Income Loss
NetIncomeLoss
197231
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-711890
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2282124 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2282124 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1002282124 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2282124 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347059
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-711890
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2058949
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
197231
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1861718
CY2023 us-gaap Net Income Loss
NetIncomeLoss
197231
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-711890
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1976
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
150235
CY2023 us-gaap Financing Interest Expense
FinancingInterestExpense
79492
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-63907
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
199159
CY2023 cik0001853630 Increase Decrease In Trade Payables
IncreaseDecreaseInTradePayables
-11901
CY2022 cik0001853630 Increase Decrease In Trade Payables
IncreaseDecreaseInTradePayables
2862
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
532437
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
412176
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
886944
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-351500
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
47103
CY2023 cik0001853630 Repaymentsof Investment And Advances In Account Of Investment
RepaymentsofInvestmentAndAdvancesInAccountOfInvestment
205000
CY2023 cik0001853630 Increase Decrease In Loans Granted
IncreaseDecreaseInLoansGranted
595000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-800000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47103
CY2023 cik0001853630 Short Term Loan From Related Parties And Shareholders Loan
ShortTermLoanFromRelatedPartiesAndShareholdersLoan
347109
CY2023 cik0001853630 Repayment Of Loans From Banking Institutions
RepaymentOfLoansFromBankingInstitutions
46214
CY2022 cik0001853630 Repayment Of Loans From Banking Institutions
RepaymentOfLoansFromBankingInstitutions
37270
CY2022 cik0001853630 Short Term Credit From Banking Institutions
ShortTermCreditFromBankingInstitutions
10071
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-393323
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-27199
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9573
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-315952
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-331596
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
451784
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
783380
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135832
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
451784
CY2021Q4 cik0001853630 Lend Money
LendMoney
25000000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3034242
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1861718
CY2023Q4 cik0001853630 Working Capital
WorkingCapital
2115889
CY2023 us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_84B_eus-gaap--BasisOfAccounting_zBZmt1tqqPGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_863_zzfQjDc4vBIb">Financial Statements Reporting Basis</span></span></b></span></td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), and are expressed in New Israeli Shekel (“NIS”) based on historical values, and provide no information on changes in the general purchasing power of the Israeli currency on the business results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report is are filed as part of Form 20-F. Since the Company was incorporated in Israel and is considered a Foreign Issuer and as such is allowed to file the statement and the financial reports in its home country currency, New Israeli Shekel (NIS).</p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_zTAgv3cALgc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_866_zeQ7VHzbZVtd">Use of Estimates</span></span></b></span></td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, which requires management to use its judgment to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. These assumptions and estimates could have a material effect on our consolidated financial statements. Actual results may differ materially from those estimates. We review our estimates on an ongoing basis based on information currently available, and changes in facts and circumstances may cause us to revise these estimates.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zRtyxaBpFXQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">K.</td><td style="text-align: justify"><span style="text-decoration: underline"><b><span id="xdx_867_zeQsBvDXBxqh">Concentrations of credit risks</span></b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial instruments include cash, accounts receivable, accounts payable, accrued expenses and loans. Balances in various cash accounts may at times exceed insured limits. We have not experienced any losses in such accounts. Cash and cash equivalents are invested in major banks in Israel and United States. Generally, these deposits may be redeemed upon demand and therefore, management believes there is minimal risk, management believes the carrying values of the financial instruments approximate their fair values because they are short term in nature or payable on demand. The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135832
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
451784
CY2023Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
17457
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
212151
CY2023Q4 cik0001853630 Governmental Institutions
GovernmentalInstitutions
24327
CY2022Q4 cik0001853630 Governmental Institutions
GovernmentalInstitutions
35716
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2676
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
44460
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
247867
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1317230
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1315811
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1419
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3395
CY2023Q4 us-gaap Line Of Credit
LineOfCredit
125000
CY2023Q4 us-gaap Escrow Deposit
EscrowDeposit
40000
CY2023Q4 us-gaap Bank Overdrafts
BankOverdrafts
2730
CY2022Q4 us-gaap Bank Overdrafts
BankOverdrafts
9039
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
13892
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
37579
CY2023Q4 us-gaap Debt Current
DebtCurrent
16622
CY2022Q4 us-gaap Debt Current
DebtCurrent
46618
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
532437
CY2022Q4 cik0001853630 Prepaid Revenue
PrepaidRevenue
139500
CY2023Q4 cik0001853630 Related Parties Payable
RelatedPartiesPayable
1489342
CY2022Q4 cik0001853630 Related Parties Payable
RelatedPartiesPayable
1779161
CY2023Q4 cik0001853630 Payable To Shareholders
PayableToShareholders
797768
CY2022Q4 cik0001853630 Payable To Shareholders
PayableToShareholders
780924
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
2819547
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
2699585
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
13892
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
37579
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16218
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
990000000 shares
CY2022Q4 cik0001853630 Ordinary Shares Issued And Outstanding
OrdinarySharesIssuedAndOutstanding
2282124 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 cik0001853630 Preferred Shares Issued And Outstanding
PreferredSharesIssuedAndOutstanding
10000000 shares
CY2021 cik0001853630 Proceed From Investors Through Registration Statement Filed With Sec
ProceedFromInvestorsThroughRegistrationStatementFiledWithSec
857945
CY2023Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
100 shares
CY2023 us-gaap Revenues
Revenues
927000
CY2022 us-gaap Revenues
Revenues
108671
CY2023 us-gaap Management Fee Expense
ManagementFeeExpense
210000
CY2022 us-gaap Management Fee Expense
ManagementFeeExpense
420000
CY2022 us-gaap Communication
Communication
1746
CY2023 us-gaap Professional Fees
ProfessionalFees
200636
CY2022 us-gaap Professional Fees
ProfessionalFees
176615
CY2022 cik0001853630 Maintenance And Electricity
MaintenanceAndElectricity
808
CY2023 cik0001853630 Office Expenses
OfficeExpenses
15729
CY2023 us-gaap Other Expenses
OtherExpenses
3747
CY2022 us-gaap Taxes Excluding Income And Excise Taxes
TaxesExcludingIncomeAndExciseTaxes
2715
CY2022 cik0001853630 Travel And Parking
TravelAndParking
342
CY2023 us-gaap Depreciation Nonproduction
DepreciationNonproduction
1976
CY2022 us-gaap Depreciation Nonproduction
DepreciationNonproduction
1641
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
432088
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
603867
CY2023 us-gaap Interest Expense
InterestExpense
74134
CY2022 us-gaap Interest Expense
InterestExpense
48525
CY2023 cik0001853630 Interest Income From Loans Granted
InterestIncomeFromLoansGranted
-4215
CY2023 cik0001853630 Foreign Exchange Differences
ForeignExchangeDifferences
9573
CY2022 cik0001853630 Foreign Exchange Differences
ForeignExchangeDifferences
-5387
CY2023 cik0001853630 Others And Banks Fees
OthersAndBanksFees
-4845
CY2022 cik0001853630 Others And Banks Fees
OthersAndBanksFees
-20274
CY2023 cik0001853630 Total Financial Expenses
TotalFinancialExpenses
84337
CY2022 cik0001853630 Total Financial Expenses
TotalFinancialExpenses
63412
CY2023Q4 cik0001853630 Pretax Loss As Reported
PretaxLossAsReported
-2993551
CY2022Q4 cik0001853630 Pretax Loss As Reported
PretaxLossAsReported
-3231473
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.23 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.23 pure
CY2023Q4 cik0001853630 Expected Tax Benefit
ExpectedTaxBenefit
688517
CY2022Q4 cik0001853630 Expected Tax Benefit
ExpectedTaxBenefit
743239
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
688517
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
743239
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
688517
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
743239
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2993551

Files In Submission

Name View Source Status
cik0001853630-20231231_lab.xml Edgar Link unprocessable
0001829126-24-003405-index-headers.html Edgar Link pending
0001829126-24-003405-index.html Edgar Link pending
0001829126-24-003405.txt Edgar Link pending
0001829126-24-003405-xbrl.zip Edgar Link pending
cik0001853630-20231231.xsd Edgar Link pending
cik0001853630-20231231_cal.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
holdme_20f.htm Edgar Link pending
holdme_ex10-6.htm Edgar Link pending
holdme_ex10-7.htm Edgar Link pending
holdme_ex12-1.htm Edgar Link pending
holdme_ex13-1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
cik0001853630-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
holdme_20f_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cik0001853630-20231231_def.xml Edgar Link unprocessable